Nuprin 75mg gastro-resistant tablets

Nazione: Irlanda

Lingua: inglese

Fonte: HPRA (Health Products Regulatory Authority)

Principio attivo:

Acetylsalicylic acid

Commercializzato da:

Accord Healthcare Ireland Ltd.

Codice ATC:

B01AC; B01AC06

INN (Nome Internazionale):

Acetylsalicylic acid

Dosaggio:

75 milligram(s)

Forma farmaceutica:

Gastro-resistant tablet

Area terapeutica:

Platelet aggregation inhibitors excl. heparin; acetylsalicylic acid

Stato dell'autorizzazione:

Marketed

Data dell'autorizzazione:

2011-07-15

Foglio illustrativo

PACKAGE LEAFLET: INFORMATION FOR THE USER
NUPRIN 75 MG GASTRO-RESISTANT TABLETS
acetylsalicylic acid (aspirin)
READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START TAKING THIS
MEDICINE BECAUSE IT CONTAINS
IMPORTANT INFORMATION FOR YOU.
-
Keep this leaflet. You may need to read it again.
-
If you have any further questions, ask your doctor or pharmacist.
-
This medicine has been prescribed for you only. Do not pass it on to
others. It may harm them,
even if their signs of illness are the same as yours.
-
If you get any side effects, talk to your doctor or pharmacist. This
includes any possible side
effects not listed in this leaflet. See section 4.
WHAT IS IN THIS LEAFLET
:
1.
What Nuprin is and what it is used for
2.
What you need to know before you take Nuprin
3.
How to take Nuprin
4.
Possible side effects
5.
How to store Nuprin
6.
Contents of the pack and other information
1. WHAT NUPRIN IS AND WHAT IT IS USED FOR
Nuprin contains acetylsalicylic acid, which in low doses belong to a
group of medicines called anti-
platelet agents. Platelets are tiny cells in the blood that cause the
blood to clot and are involved in
thrombosis. When a blood clot occurs in an artery it stops the blood
flowing and cuts off the oxygen
supply. When this happens in the heart it can cause a heart attack or
angina; in the brain it can cause a
stroke.
Nuprin is taken to reduce the risk of blood clots forming and thereby
prevent further:
-
heart attacks
-
strokes
-
cardiovascular problems in patients who suffer from stable or unstable
angina (a type of chest
pain).
Nuprin is also used to prevent the formation of blood clots after
certain types of heart surgery in order
to widen or to unblock the blood vessels.
This medicinal product is not recommended for emergencies. It can only
be used as a preventive
treatment.
2.
WHAT YOU NEED TO KNOW BEFORE YOU TAKE NUPRIN
DO NOT TAKE NUPRIN IF YOU
-
are allergic to acetylsalicylic acid or any of the ingredients of this
medicine (listed in section 6)
-
are allergic to other salicylates or non-steroid

Scheda tecnica

Health Products Regulatory Authority
24 October 2022
CRN00CZ08
Page 1 of 10
SUMMARY OF PRODUCT CHARACTERISTICS
1 NAME OF THE MEDICINAL PRODUCT
Nuprin 75mg gastro-resistant tablets
2 QUALITATIVE AND QUANTITATIVE COMPOSITION
Each gastro-resistant tablet contains 75mg acetylsalicylic acid
(aspirin).
For the full list of excipients, see section 6.1.
3 PHARMACEUTICAL FORM
Gastro-resistant tablet.
75 mg: Yellow to light yellow, oval, biconvex gastro-resistant
tablets, 9.2 x 5.2 mm.
4 CLINICAL PARTICULARS
4.1 THERAPEUTIC INDICATIONS
- Secondary prevention of myocardial infarction.
- Prevention of cardiovascular morbidity in patients suffering from
stable angina pectoris.
- History of unstable angina pectoris, except during the acute phase.
- Prevention of graft occlusion after Coronary Artery Bypass Grafting
(CABG).
- Coronary angioplasty, except during the acute phase.
- Secondary prevention of transient ischaemic attacks (TIA) and
ischaemic cerebrovascular accidents (CVA), provided
intracerebral haemorrhages have been ruled out.
Nuprin is not recommended in emergency situations. It is restricted to
secondary prevention with chronic treatment.
4.2 POSOLOGY AND METHOD OF ADMINISTRATION
Adults
_Secondary prevention of myocardial infarction:_
The recommended dose is 75-160 mg once daily.
_Prevention of cardiovascular morbidity in patients suffering from
stable angina pectoris:_
The recommended dose is 75-160 mg once daily.
_History of unstable angina pectoris, except during the acute phase:_
The recommended dose is 75-160 mg once daily.
_Prevention of graft occlusion after Coronary Artery Bypass Grafting
(CABG):_
The recommended dose is 75-160 mg once daily.
_Coronary angioplasty, except during the acute phase:_
The recommended dose is 75-160 mg once daily.
_Secondary prevention of transient ischaemic attacks (TIA) and
ischaemic cerebrovascular accidents (CVA), provided intracerebral _
_haemorrhages have been ruled out:_
The recommended dose is 75-325 mg once daily.
Elderly
Health Products Regulatory Authority
24 October